Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a key medication option for patients with type 2 diabetes and are a component of guideline-directed medical therapy for patients with heart failure with reduced ejection fraction (HFrEF).1
A 2022 meta-analysis published in The Lancet analyzed data from five clinical trials, including the DELIVER trial and the EMPEROR-Preserved trial, provides data to support the use of SGLT2i in heart failure with both reduced and preserved ejection fraction, independent of diabetes status.2-4 SGLT2i were found to reduce the risk of the composite and individual outcomes for cardiovascular death and hospitalization for heart failure; all-cause mortality was also reduced. Among all five trials, treatment with SGLT2i reduced the risk of cardiovascular death or hospitalization for heart failure, with a number needed to treat of 25. This meta-analysis adds to the growing evidence supporting SGLT2i use in heart failure across the spectrum of heart failure severity and patient characteristics.2
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi.org/10.1161/CIR.0000000000001063.
- Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-767. doi:10.1016/S0140-6736(22)01429-5.
- Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038.